MoBiT

MoBiT:

Three leading products BAB-05, BAB-09 and BAB-0120 are in late preclinical stage. Outstanding efficacies and safety profiles have been demonstrated in rodents and NHP. IND application is expected in Q2/2026 (BAB-05) and Q4/2026 (BAB-09), respectively.

  • Long-acting monovalent BiTE targeting CD3 and CD19 with high specificity
  • High production yield in stable CHO expression system
  • High homogeneity and stability, similar to those of mAbs, suitable for dosing subcutaneously
  • T cell-dependent cytotoxicity toward CD19+ cells
  • Optimal cytokine release profile due to moderate T cell activation
  • Effectively deplete B cells and activate T cells in NHPs
  • Broad indications of B-cell hematological tumors and B-cell autoimmune diseases
  • Long-acting monovalent BiTE targeting CD3 and PSMA with high specificity
  • High production yield in stable CHO expression system
  • High homogeneity and stability
  • T cell-dependent cytotoxicity toward PSMA+ cells
  • Optimal cytokine release profile due to moderate T cell activation
  • Indication: castrate resistant prostate cancer
  • Long-acting monovalentbispecific antibody targeting EGFR and cMet
  • High production yield in stable CHO expression system
  • High homogeneity and stability
  • Inhibit downstream phosphorylation signal of EGFR and cMet
  • Optimal affinity profile on each target
  • Synergize with TKI to overcome resistance issues 
Scroll to Top